Free Trial

This company has been marked as potentially delisted and may not be actively trading.

OTCMKTS:VRACY

Viralytics (VRACY) Stock Price, News & Analysis

Viralytics logo

About Viralytics Stock (OTCMKTS:VRACY)

Advanced Chart

Key Stats

Today's Range
$3.75
$3.75
50-Day Range
N/A
52-Week Range
$1.50
$4.10
Volume
N/A
Average Volume
247 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Viralytics Limited, a biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies in Australia and internationally. The company's lead investigational product is CAVATAK, a proprietary formulation of an oncolytic common cold virus that is in Phase Ib clinical trials for the treatment of melanoma, and lung and bladder cancer; Phase II clinical trials for the treatment of late stage melanoma; and in pre-clinical studies for the treatment of prostate and breast cancer, multiple myeloma, pancreatic cancer, malignant glioma, acute myeloid leukemia, and chronic lymphocytic leukemia. It is also developing EVATAK to treat ovarian, prostate, and gastric cancer. The company was formerly known as Psiron Ltd. and changed its name to Viralytics Limited in December 2006. Viralytics Limited is headquartered in Sydney, Australia. As of June 20, 2018, Viralytics Limited operates as a subsidiary of Merck Sharp & Dohme (Holdings) Pty Ltd.

Receive VRACY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viralytics and its competitors with MarketBeat's FREE daily newsletter.

VRACY Stock News Headlines

Vladimir Lenin was right…
The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.
ViewRay, Inc. (VRAY)
50% Off Ray-Ban Promo Codes - March
Lenses and ray diagrams - OCR Gateway
Top broker names 3 healthcare shares to buy
See More Headlines

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Commercial Physical Research
Sub-Industry
N/A
Current Symbol
OTCMKTS:VRACY
Previous Symbol
NASDAQ:VRACY
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (OTCMKTS:VRACY) was last updated on 5/24/2025 by MarketBeat.com Staff
From Our Partners